Kalqyl publishes analysis of Stayble TherapeuticsSeptember 2022
Stayble Therapeutics AB (“Stayble” or the “Company”) has recently entered into an agreement with the analysis company Kalqyl AB (“Kalqyl”) which has now published the first analysis of Stayble.
In order to increase understanding of Stayble’s business and the status of the Company, Kalqyl has been appointed to conduct an analysis of Stayble. In addition to presenting upcoming triggers, the analysis includes an independent review of Stayble’s treatment, market potential and the competitive situation. Chronic disc-related back pain is reported to be one of the major public health problems and Stayble has the potential to address a major market need. Going forward, Kalqyl will monitor Stayble on an ongoing basis and publish updated analyses.
“The key value driver in Stayble will be the study results from the ongoing Phase 2b study. This may also pave the way for the next major catalyst, which is a licensing agreement for STA363. If the positive results from previous studies can be replicated, we believe the company is facing a significant positive valuation,” writes the analyst from Kalqyl AB.
Read the full analysis here: https://kalqyl.se/initial-take-stayble-therapeutics
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
Phone: +46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.
Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser and can be reached at +46 (0) 11 32 30 732 or e-mail firstname.lastname@example.org